NCT07088133View on ClinicalTrials.gov

Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus

NANot yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

August 1, 2026

Conditions
HBV InfectionHCC - Hepatocellular Carcinoma
Interventions
DRUG

NA(s)+HT-102+FD-001

Nucleos(t)ide analogues will be administrated throughout the entire treatment course; Patients will be injected with HT-102 once in Day1 (Week1), Day8 (Week2), Day15 (Week3), Day22 (Week4); Patients will be injected with FD-001 once in Day29 (Week5), Day57 (Week9), Day85 (Week13), Day113 (Week17), Day141 (Week21), Day169 (Week25) after confirmed reduction of serum HBsAg to below 10 IU/mL.

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT07088133 - Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus | Biotech Hunter | Biotech Hunter